Volume 7.32 | Aug 20

Mammary Cell News 7.32 August 20, 2015
Mammary Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook   MCN on Twitter
 
TOP STORY
Stiffer Breast Tissue in Obese Women Promotes Tumors
Investigators explained how obesity changes the consistency of breast tissue in ways that are similar to tumors, thereby promoting disease. They showed that obesity leads to a stiffening of a meshwork of material that surrounds fat cells in the breast, called the extracellular matrix, and these biomechanical changes create the right conditions for tumor growth. [Press release from Cornell University discussing online prepublication in Science Translation Medicine] Press Release | Abstract
Request a Copy: Breast Cancer Wallchart
 
PUBLICATIONS (Ranked by impact factor of the journal)
LABORATORY RESEARCH

Podocalyxin-Like Protein 1 Functions as an Immunomodulatory Molecule in Breast Cancer Cells
Researchers determined the effect of podocalyxin-like protein 1 overexpressed in MCF7 breast cancer cells on natural killer cell cytotoxicity, dendritic cell maturation, and agonist-induced T cell proliferation. [Cancer Lett] Abstract

ABCG2 Transporter Inhibitor Restores the Sensitivity of Triple Negative Breast Cancer Cells to Aminolevulinic Acid-Mediated Photodynamic Therapy
Photosensitizer protoporphyrin IX (PpIX) fluorescence, intracellular localization and cell response to photodynamic therapy were analyzed in MCF10A normal breast epithelial cells and a panel of human breast cancer cells including estrogen receptor positive, human epidermal growth factor receptor 2 positive and triple negative breast cancer cells after treatment with PpIX precursor aminolevulinic acid. [Sci Rep] Full Article

Leptin Produced by Obese Adipose Stromal/Stem Cells Enhances Proliferation and Metastasis of Estrogen Receptor Positive Breast Cancers
Estrogen receptor positive breast cancer cells (BCCs) were co-cultured with leptin shRNA adipose stromal/stem cells (ASCs) isolated from lean women or leptin shRNA ASCs isolated from obese women and changes in the proliferation, migration, invasion, and gene expression of BCCs were investigated. [Breast Cancer Res] Full Article

Brief-Exposure to Preoperative Bevacizumab Reveals a TGF-β Signature Predictive of Response in HER2-Negative Breast Cancers
In order to best define biomarkers of response, and to shed insight on mechanism of action of certain clinically important agents for early breast cancer, researchers used a brief-exposure paradigm in the preoperative setting to study transcriptional changes in patient tumors that occur with one dose of therapy prior to combination chemotherapy. [Int J Cancer] Abstract

ADAM10: A New Player in Breast Cancer Progression?
ADAM10 expression was decreased by RNA interference and the effects of this on cell numbers, invasion and migration were determined. Investigators also examined the effect of ADAM10 inhibition on breast cancer cell line invasion and migration. [Br J Cancer] Full Article

Adipocytes Can Induce Epithelial-Mesenchymal Transition in Breast Cancer Cells
Researchers investigated the involvement of adipocytes in the epithelial-mesenchymal transition (EMT) in breast cancer. Breast cancer cell lines MCF-7, MDA-MB-453, MDA-MB-435S, MDA-MB-231, and MDA-MB-468 were co-cultured with adipocytes and analyzed for morphological changes, proliferation activity, EMT markers, migration, and invasion. [Breast Cancer Res Treat] Abstract

N1-Guanyl-1,7-Diaminoheptane Sensitizes Estrogen Receptor Negative Breast Cancer Cells to Doxorubicin by Preventing Epithelial-Mesenchymal Transition through Inhibition of Eukaryotic Translation Initiation Factor 5A2 Activation
Researchers found that N1-guanyl-1,7-diaminoheptan enhanced doxorubicin cytotoxicity in estrogen receptor (ER)-negative HCC1937 cells but had little effect in ER-positive MCF-7 and Bcap-37 cells. [Cell Physiol Biochem] Abstract | Full Article

Identification of miR-200a as a Novel Suppressor of Connexin-43 in Breast Cancer Cells
Overexpression of connexin 43 (Cx43) in MCF-7 cells potentiated the migration activity, while additional miRNA (miR)-200a treatment notably prevented this effect. Researchers also demonstrated that decreased levels of miR-200a and elevated expression of Cx43 in the metastatic breast cancer tissues versus the primary ones. [Biosci Rep] Abstract

Claudin 1 Promotes Migration and Increases Sensitivity to Tamoxifen and Anticancer Drugs in Luminal-Like Human Breast Cancer Cells MCF7
Claudin 1 promoted migration in luminal-like MCF7 human breast cancer cells and increased their sensitivity to tamoxifen, etoposide, and cisplatin. They also observed an inverse relationship between upregulation of claudin 1 and TGFβ. [Cancer Invest] Abstract

CLINICAL RESEARCH

Neoadjuvant plus Adjuvant Bevacizumab in Early Breast Cancer (NSABP B-40 [NRG Oncology]): Secondary Outcomes of a Phase III, Randomized Controlled Trial
Patients received one of three docetaxel-based neoadjuvant regimens for four cycles: docetaxel alone with addition of capecitabine or with addition of gemcitabine, all followed by neoadjuvant doxorubicin and cyclophosphamide every three weeks for four cycles. [Lancet Oncol] Abstract

Octreotide LAR and Tamoxifen Versus Tamoxifen in Phase III Randomize Early Breast Cancer Trials: NCIC CTG MA.14 and NSABP B-29
NCIC CTG MA.14 and NSABP B-29 trials examined the addition of Octreotide LAR to five years of tamoxifen. The primary endpoint was disease-free survival, defined as time from randomization to time of breast cancer recurrence; second primary cancer other than squamous or basal cell skin carcinoma, cervical carcinoma in situ, or lobular breast carcinoma in situ; or death. [Breast Cancer Res Treat] Abstract

Apply Now: Mammary Stem Cells Training Course (October 6-7, 2015) in Vancouver, Canada
 
REVIEWS
Impact of Progesterone on Stem/Progenitor Cells in the Human Breast
The authors summarize recent work regarding the impact of progesterone action on the stem/progenitor cell compartment of the human breast. [J Mammary Gland Biol Neoplasia] Abstract

Visit our reviews page to see a complete list of reviews in the mammary cell research field.
 
INDUSTRY NEWS
TapImmune Completes Transfer of IND from the Mayo Clinic
TapImmune, Inc. announced the successful conveyance of the Mayo Clinic IND (Investigational New Drug application) to TapImmune as part of the recently completed licensing agreement. The transfer marks a critical step in reaching the company’s major milestone of initiating TapImmune’s sponsored Phase II trials in patients with triple-negative breast cancer or ovarian cancer. [TapImmune, Inc.] Press Release

ASLAN Pharmaceuticals Receives Orphan Drug Designation from the FDA for ASLAN001 (Varlitinib) in Cholangiocarcinoma
ASLAN Pharmaceuticals announced the designation as an Orphan drug of their pan-HER inhibitor ASLAN001 by the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development. ASLAN001 is currently being tested in Phase II studies in breast cancer and cholangiocarcinoma. [ASLAN Pharmaceuticals ] Press Release

Canadian Breast Cancer Foundation Announces $7.5 Million Investment in New Research
Researchers in Ontario are zeroing in on innovative solutions to breast cancer, thanks to an investment in new grants by Canadian Breast Cancer Foundation. With the support of our generous donors, Canadian Breast Cancer Foundation–Ontario Region is pleased to announce $7.5 million in funding for 24 new research project grants and fellowship awards. [Canadian Breast Cancer Foundation] Press Release

From our sponsor:
Looking for ALDH+ cancer stem cells?
Watch a video to see how ALDEFLUOR™ can help.
 
POLICY NEWS
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
 
EVENTS
NEW Advances in Breast Cancer Research
October 17-20, 2015
Bellevue, Washington

Visit our events page to see a complete list of events in the mammary cell community.
 
JOB OPPORTUNITIES
NEW Postdoctoral Fellow – Proteomic, Glycomic and Autoantibody Biomarkers of Cancer (Fred Hutchinson Cancer Research Center)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)

Postdoctoral Fellow – Cancer Biology (National Cancer Institute)

Postdoctoral Researcher – Translational Breast Cancer Research (Dublin City University)

Postdoctoral Position – Cancer Biology (Northwestern University)

Postdoctoral Position – Inflammation & Breast Tumor Metastasis (Stephenson Cancer Center)

Postdoctoral Fellow – Cancer Research (National University of Singapore)

Postdoctoral Research Fellow (Fred Hutchinson Cancer Research Center)

Research Associate/Assistant Professor – Breast Cancer (University of Chicago)

Postdoctoral Research Associate – Breast Stem Cell Biology (University of Miami Miller School of Medicine)


Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
 

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Mammary Cell News: Archives | Events | Contact Us